Published in Healthcare Finance, Tax and Law Weekly, October 18th, 2006
Bugg will retain his current duties as CEO until a replacement has taken office, at which time he will become non-executive chairman of BioCryst. A board sub-committee, to be chaired by Beth C. Seidenberg, MD, Partner at Kleiner Perkins Caufield & Byers, and including Zola P. Horovitz, PhD, lead director of BioCryst and former VP, Business Development and Planning at Bristol-Myers Squibb Co. and William W. Featheringill, president and CEO of Private Capital Corp., will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly